8-K: Trevi Therapeutics Reports Q1 2026 Results, Extends Cash Runway

Trevi Therapeutics announced Q1 2026 financial results, highlighting progress in chronic cough indications and a significant capital raise extending cash runway into 2030.

Summary

• Trevi Therapeutics reported financial results for the quarter ended March 31, 2026.
• The company completed a follow-on common stock offering in April 2026, raising approximately $162 million in net proceeds.
• This capital raise is expected to extend the company's cash runway into 2030, sufficient to fund development through potential FDA approval of Haduvio for IPF-related chronic cough.
• Clinical development plans for chronic cough indications remain on track.
• Research and development expenses increased to $9.9 million in Q1 2026 from $7.8 million in Q1 2025.
• General and administrative expenses rose to $5.0 million in Q1 2026 from $3.7 million in Q1 2025.
• The net loss for Q1 2026 was $13.2 million, compared to a net loss of $10.3 million in Q1 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to the successful capital raise, extended cash runway, and progress in clinical development, despite increased operating expenses and net loss, which are typical for the industry.

Positives

• Completed a follow-on common stock offering in April 2026, raising approximately $162 million in net proceeds.
• Extended expected cash runway into 2030, sufficient to fund development through potential FDA approval of Haduvio in IPF-related chronic cough.
• End-of-Phase 2 meeting with the FDA for IPF-related chronic cough showed overall alignment on the clinical development plan.
• Received a notice to grant a European patent covering nalbuphine ER for IPF-related chronic cough, with expected expiration in 2039.
• Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC.
• Significant unmet need and no FDA-approved therapies exist for chronic cough in IPF and non-IPF ILD patients.
• Cash, cash equivalents, and marketable securities totaled $171.8 million at the end of Q1 2026.

Negatives

• Net loss for Q1 2026 was $13.2 million, an increase from $10.3 million in Q1 2025.
• Research and development expenses increased to $9.9 million in Q1 2026 from $7.8 million in Q1 2025.
• General and administrative expenses increased to $5.0 million in Q1 2026 from $3.7 million in Q1 2025, partly due to higher legal fees and stock option expenses.

Risks

• Uncertainties inherent in estimating Trevi's cash runway, future expenses, and ability to fund future operations, including clinical trials.
• Uncertainties regarding the success, cost, and timing of product candidate development activities and clinical trials.
• The risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials.
• Uncertainties regarding Trevi's ability to execute on its strategy.
• Uncertainties with respect to regulatory authorities' views on clinical trial data and next steps for Haduvio development.
• Potential for delays in initiating clinical trials, such as the Phase 2b trial for non-IPF ILD-related chronic cough and the Phase 2b trial for RCC, pending FDA meetings and protocol reviews.
• The safety and efficacy of Haduvio have not been evaluated by any regulatory authority.

Future Outlook

The company expects its current cash resources to extend its cash runway into 2030, sufficient to fund the development of Haduvio for IPF-related chronic cough through potential FDA approval. It also anticipates funding the Phase 2b trial for non-IPF ILD-related chronic cough and the Phase 2b trial for RCC, including reporting topline data from these trials. These projections do not include commercial launch expenses.

Management Comments

• "We are entering an important phase of execution for Trevi, with study initiations anticipated across our chronic cough programs."
• "Following a very productive End-of-Phase 2 meeting with the FDA on our lead program in IPF-related chronic cough, we are excited to initiate multiple clinical trials this quarter, including our first Phase 3 in IPF-related chronic cough and our Phase 2b in RCC."
• "With an expected cash runway into 2030, we are well-positioned to execute on our development strategy and advance towards a potential FDA submission in IPF-related chronic cough."
• "We believe successful execution of our strategy would establish Trevi as the leader in providing best-in-class therapy in chronic cough indications with significant unmet needs and no FDA-approved therapies."

Industry Context

StockSavvy.ai notes that Trevi Therapeutics is operating in the highly competitive and regulated biopharmaceutical sector, focusing on rare disease indications with significant unmet medical needs. The company's strategy hinges on advancing its lead candidate, Haduvio, through late-stage clinical trials and towards potential FDA approval, a path common among clinical-stage biotechs. The successful capital raise provides crucial runway, a critical factor for companies in this space that often require substantial funding for lengthy development cycles.

Comparison to Industry Standards

• Companies in the biopharmaceutical sector often undertake significant capital raises to fund late-stage clinical trials, similar to Trevi's $162 million offering.
• Extending cash runway into 2030 is a strong positive for a clinical-stage company, providing stability and time to achieve key development milestones, which is a benchmark for investor confidence.
• The focus on indications with high unmet needs and no FDA-approved therapies, such as chronic cough in IPF and RCC, is a common strategy for biotechs seeking to establish market leadership and secure premium pricing upon approval.

Stakeholder Impact

• Shareholders benefit from the extended cash runway and progress towards potential FDA approval, reducing near-term dilution risk and increasing potential future value.
• Employees are supported by the company's strengthened financial position, allowing for continued execution of development plans.
• Patients with chronic cough indications (IPF, non-IPF ILD, RCC) stand to benefit from the advancement of Haduvio, a potential therapy for conditions with significant unmet needs and no current FDA-approved treatments.

Next Steps

• Initiate multiple clinical trials this quarter, including the first Phase 3 in IPF-related chronic cough and the Phase 2b in RCC.
• Conduct two Phase 3 trials in parallel for IPF-related chronic cough, with the first expected to initiate in Q2 2026 and the second in H2 2026.
• Initiate an adaptive design Phase 2b clinical trial for non-IPF ILD-related chronic cough in H2 2026, subject to FDA meeting.
• Host an Investor and Analyst Day on May 7, 2026.
• Present data highlights from ATS 2026 presentations at an investor and analyst event on May 18, 2026.

Key Dates

Recommendation

The company has made significant progress with its clinical pipeline and secured substantial funding, extending its cash runway. However, the path to FDA approval for Haduvio remains long and subject to clinical trial success and regulatory review. While positive, the current stage of development warrants a 'hold' recommendation, allowing investors to monitor trial results and regulatory interactions.

Keywords

Trevi Therapeutics, Haduvio, Chronic Cough, IPF, Nalbuphine ER, Clinical Trials, Biopharmaceutical, FDA